Bridge to Life adquiere el sistema VitaSmart™ de Medica S.p.A.
Deal News | Dec 18, 2024 | PR Newswire Cision Bridge to Life, Ltd.
Bridge to Life Ltd., a leader in organ preservation solutions, has acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A., an Italian biomedical and medical technology group with a strong international presence. This acquisition includes exclusive worldwide brand rights and the potential to register the VitaSmart™ trademark globally. By incorporating VitaSmart™ into their offerings, Bridge to Life aims to enhance transplant medicine with the system's proven efficacy in over 5,000 liver perfusions worldwide. CEO Don Webber highlighted the functional and user-friendly design of VitaSmart™, emphasizing its minimal monitoring requirements and its potential to improve organ preservation outcomes. Bridge to Life plans to file an FDA application for VitaSmart in early 2025, anticipating expanded access to US transplant centers, organ procurement organizations, and patients awaiting viable liver transplants. The company envisions increased enterprise value and demand capacity through this acquisition. The move aligns with Bridge to Life's mission to improve transplant outcomes and save more lives.
Sectors
- Healthcare Technology
- Biomedical
- Organ Transplantation
Geography
- United States – Bridge to Life Ltd. is preparing to file for FDA approval to enter the US market with the VitaSmart™ system.
- Italy – Medica S.p.A., the former owner of the VitaSmart™ System, is based in Mirandola, Italy.
Industry
- Healthcare Technology – Bridge to Life's acquisition of the VitaSmart™ System pertains to innovative medical devices, impacting organ preservation and transplant technology.
- Biomedical – Medica S.p.A.'s involvement specializes in biomedicine, with a focus on technological advancements in medical devices, particularly in organ preservation.
- Organ Transplantation – The article revolves around the acquisition of a system that improves organ transplantation outcomes, demonstrating relevance to this sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Bridge to Life Ltd. | Bidding Companybuyer | Company | Bridge to Life is a leading provider of organ preservation solutions aiming to enhance transplant outcomes globally. |
| Medica S.p.A. | Selling Company | Company | An Italian integrated biomedical and medical technology group engaged in product development for blood and water purification. |
| Don Webber | CEO and President | Person | CEO and President of Bridge to Life Ltd., overseeing the strategic acquisition of VitaSmart™. |